Prenatal genetic test company Ariosa Diagnostics sets terms for $60 million IPO

By
A A A

Ariosa Diagnostics, which provides genetic tests that determine fetal conditions and characteristics for expectant mothers, announced terms for its IPO on Thursday. The San Jose, CA-based company plans to raise $60 million by offering 3.5 million shares at a price range of $16 to $18. At the midpoint of the proposed range, it would command a fully diluted market value of $323 million.

Ariosa Diagnostics, which was founded in 2008 and booked $63 million in sales for the 12 months ended March 31, 2014, plans to list on the NASDAQ under the symbol AROS. Ariosa initially filed confidentially on December 19, 2013. J.P. Morgan and Citi are the joint bookrunners on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: AROS

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

33,110,376
  • $113.99 ▲ 1.77%
25,034,179
    $17.98 unch
24,486,872
  • $7.41 ▲ 2.07%
20,864,535
  • $7.39 ▼ 2.76%
18,600,501
  • $8.30 ▼ 0.36%
17,530,211
  • $8.14 ▲ 3.17%
17,299,208
  • $93.79 ▲ 2.74%
14,669,760
  • $25.78 ▼ 0.19%
As of 12/26/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com